Followers | 372 |
Posts | 20770 |
Boards Moderated | 4 |
Alias Born | 04/08/2011 |
Tuesday, January 15, 2019 1:53:31 PM
Published: Jan 15, 2019 11:16 a.m. ET
Jan 15, 2019 (TheNewswire.ca via COMTEX) -- (via TheNewswire)
- Lexaria Nicotine LLC and a subsidiary of Altria Group, Inc. have entered into a definitive investment agreement.
- The Altria investment will fund research on regulatory compliant, oral forms of nicotine delivery.
- Altria has been granted exclusive DehydraTECH(TM) license rights to commercialize oral nicotine products in the United States.
- Lexaria Bioscience retains majority equity ownership of Lexaria Nicotine LLC.
Kelowna, British Columbia / TheNewswire / January 15, 2019 - Lexaria Bioscience Corp. (otcqx:LXRP) (cse:LXX) ("Lexaria Bioscience"), a drug delivery platform innovator, is pleased to announce that its wholly-owned subsidiary Lexaria Nicotine LLC ("Lexaria Nicotine") and Altria Ventures Inc., an indirect wholly owned subsidiary of Altria Group, Inc. MO, -0.51% ("Altria"), have executed definitive agreements to pursue innovation in oral, reduced risk nicotine consumer products using Lexaria's patented DehydraTECH(TM) technology. Lexaria's DehydraTECH(TM) technology enhances the performance of beneficial compounds in ingestible products across four categories: taste & smell, speed of action, bio-absorption and bioavailability.
Funding
Altria is funding a milestone-based research & development program ("R&D Program") in exchange for a minority equity interest in Lexaria Nicotine and certain DehydraTECH(TM) license rights. Altria will provide initial funding of US$1 million, with the option for additional funding of up to US$12 million through multiple phased private financings.
R&D Program
Lexaria Nicotine will execute a comprehensive series of clinical investigations of oral forms of nicotine delivery, utilizing Lexaria's patented DehydraTECHTM technology.
DehydraTECH(TM) License
Altria has been granted a license to use Lexaria Bioscience's patented DehydraTECH(TM) technology for oral nicotine delivery forms on an exclusive basis in the United States and a non-exclusive basis elsewhere globally. Altria will pay Lexaria Nicotine a royalty on revenue generated from the sale of nicotine products containing DehydraTECH(TM), until such time it may acquire 100% ownership in Lexaria Nicotine.
Additional Information
Altria will initially have the right to appoint one of the seven directors on Lexaria Nicotine's board of directors and, through the additional phased investments, may have the right to appoint up to three of the seven directors.
Altria has the option to acquire 100% ownership interest in Lexaria Nicotine commensurate with then-current fair market value. Lexaria Bioscience has not sold or optioned any of its own equity. As announced on October 10, 2018, Lexaria Bioscience has created a number of individual subsidiaries - including Lexaria Nicotine - in a structure whereby Lexaria Bioscience retains ownership of its patented DehydraTECH(TM) technology and licenses its use to multiple molecular classes, including nicotine.
Management Commentary
"Lexaria Bioscience is proud that, after careful selection, Altria has chosen to fund research into DehydraTECH(TM) technology and potentially commercialize this technology for oral nicotine," remarks Chris Bunka, CEO of Lexaria Bioscience. "This partnership will provide significant benefits to Lexaria Bioscience and its shareholders with a world-class R&D Program and regulatory compliance process. We believe Altria is the best corporate partner we could work with to truly make a difference in the lives of millions of consumers."
"Lexaria Bioscience has repeatedly demonstrated the powerful effects of its patented DehydraTECH(TM) technology for enhancing the palatability and speed of onset of orally-consumed bioactive substances such as nicotine," added John Docherty, President of Lexaria Bioscience. "Laboratory research to date on oral nicotine formulations has been quite encouraging. We are very excited to advance the clinical phases of our comprehensive R&D Program together with Altria with a view to full commercial product development."
Advisors
Borden Ladner Gervais LLP acted as independent legal counsel to Lexaria Bioscience and Lexaria Nicotine. Hunton Andrews Kurth LLP acted as independent legal counsel to Altria.
About Lexaria Bioscience
Lexaria Bioscience Corp. has developed and out-licenses its disruptive delivery technology that promotes healthier ingestion methods, lower overall dosing and quicker onset of lipophilic active molecules. Lexaria has ten patents granted in the USA and in Australia and has filed over 50 patent applications worldwide across ten patent families. Lexaria's technology provides more rapid delivery to the bloodstream; and important taste-masking benefits, for orally administered bioactive molecules including cannabinoids, vitamins, non-steroidal anti-inflammatory drugs (NSAIDs), nicotine and other molecules.
www.lexariabioscience.com
Lexaria Nicotine LLC is a United States domiciled, majority-owned subsidiary of Lexaria Bioscience Corp., focused on reduced-risk nicotine solutions.
www.lexarianicotineco.com
For regular updates, connect with Lexaria on Twitter https://twitter.com/lexariacorp
and on Facebook https://www.facebook.com/lexariabioscience/
About Altria Group
Altria's wholly-owned subsidiaries include Philip Morris USA Inc. (PM USA), U.S. Smokeless Tobacco Company LLC (USSTC), John Middleton Co. (Middleton), Sherman Group Holdings, LLC and its subsidiaries (Nat Sherman), Ste. Michelle Wine Estates Ltd. (Ste. Michelle) and Philip Morris Capital Corporation (PMCC). Altria holds an equity investment in Anheuser-Busch InBev SA/NV (AB InBev).
The brand portfolios of Altria's tobacco operating companies include Marlboro(R), Black & Mild(R), Copenhagen(R) and Skoal(R). Ste. Michelle produces and markets premium wines sold under various labels, including Chateau Ste. Michelle(R), Columbia Crest(R), 14 Hands(R) and Stag's Leap Wine Cellars(TM), and it imports and markets Antinori(R), Champagne Nicolas Feuillatte(TM), Torres(R) and Villa Maria Estate(TM) products in the United States. Trademarks and service marks related to Altria referenced in this release are the property of Altria or its subsidiaries or are used with permission. More information about Altria is available at altria.com and on the Altria Investor app.
Take a closer look at Altria and its companies on altria.com.
Follow Altria on Twitter at @AltriaNews.
FOR FURTHER INFORMATION PLEASE CONTACT:
Damn it feels good to be a gangster.
Recent MO News
- Altria and NJOY Respond to ITC Initial Determination in Complaint Against NJOY • Business Wire • 08/27/2024 12:00:00 PM
- Cruise and Uber Join Forces for Robotaxis, Alibaba Shifts Primary Listing to Hong Kong, Altria Hikes Dividend 4.1% • IH Market News • 08/23/2024 12:20:26 PM
- Altria Increases Quarterly Dividend by 4.1% to $1.02 Per Share • Business Wire • 08/22/2024 05:15:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 07/31/2024 11:23:37 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/31/2024 11:02:01 AM
- Altria Reports 2024 Second-Quarter and First-Half Results; Narrows 2024 Full-Year Earnings Guidance • Business Wire • 07/31/2024 11:00:00 AM
- US Index Futures Up Ahead of Fed Decision; Oil Prices Surge Amid Middle East Tensions • IH Market News • 07/31/2024 10:01:30 AM
- Altria to Host Webcast of 2024 Second-Quarter and First-Half Results • Business Wire • 07/17/2024 02:00:00 PM
- Altria Announces PMTA Submission for on! PLUS™ Nicotine Pouches • Business Wire • 06/26/2024 08:52:00 PM
- UPS Divests Coyote Logistics in $1.025 Billion Deal with RXO, Under Armour Agrees to $434 million Settlement, and More News • IH Market News • 06/24/2024 11:00:20 AM
- NJOY Receives First FDA Authorizations for Menthol E-Vapor Products • Business Wire • 06/21/2024 10:17:00 PM
- Form 11-K - Annual report of employee stock purchase, savings and similar plans • Edgar (US Regulatory) • 06/07/2024 04:58:50 PM
- Form 11-K - Annual report of employee stock purchase, savings and similar plans • Edgar (US Regulatory) • 06/07/2024 04:57:12 PM
- Form 10-K/A - Annual report [Section 13 and 15(d), not S-K Item 405]: [Amend] • Edgar (US Regulatory) • 06/05/2024 05:23:49 PM
- NJOY Submits Premarket Tobacco Product Applications to the FDA for NJOY ACE 2.0 Featuring Bluetooth®-enabled Access Restriction Technology • Business Wire • 05/20/2024 08:15:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/20/2024 06:47:54 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/20/2024 06:47:27 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/20/2024 06:47:13 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/20/2024 06:46:55 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/20/2024 06:46:40 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/20/2024 06:46:27 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/20/2024 06:46:14 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/20/2024 06:46:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/20/2024 06:45:50 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/20/2024 06:45:36 PM
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM
Dear Cashmere Group Holding Co. AKA Swifty Global Signs Binding Letter of Intent to be Acquired by Signing Day Sports • DRCR • Sep 19, 2024 10:26 AM
HealthLynked Launches Virtual Urgent Care Through Partnership with Lyric Health. • HLYK • Sep 19, 2024 8:00 AM
Element79 Gold Corp. Appoints Kevin Arias as Advisor to the Board of Directors, Strengthening Strategic Leadership • ELMGF • Sep 18, 2024 10:29 AM
Mawson Finland Limited Further Expands the Known Mineralized Zones at Rajapalot: Palokas step-out drills 7 metres @ 9.1 g/t gold & 706 ppm cobalt • MFL • Sep 17, 2024 9:02 AM
PickleJar Announces Integration With OptCulture to Deliver Holistic Fan Experiences at Venue Point of Sale • PKLE • Sep 17, 2024 8:00 AM